Kiora Pharmaceuticals, Inc. · NASDAQ:KPRX

Kiora Pharmaceuticals — Investor Presentation (October 2026)

29 slides from Kiora Pharmaceuticals's investor presentation, Oct 29, 2026

  1. Slide 1: Kiora Pharmaceuticals, Inc. Q4 2026 Corporate Overview

    Kiora Pharmaceuticals, Inc. Q4 2026 | Corporate Overview

  2. Slide 2: Legal Disclaimers

    Legal Disclaimers This presentation is provided for informational purposes only. Some of the material and statements in this presentation are "forward-looking" statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, wi

  3. Slide 3: Expanding Kiora's Late-Stage Retinal Therapeutics Pipeline

    Expanding Kiora’s Late-Stage Retinal Therapeutics Pipeline Added neuroprotective oral calpain inhibitor for CRAO with planned development in NAION KIO-401 KIO-301 New Phase 3-ready asset Existing Phase 2 asset for Central Retinal Artery Occlusion for late-stage Retinitis Pigmentosa (from Senju Pharm

  4. Slide 4: Targeting the Retina to Slow or Stop Vision Loss or Restore Sight

    Targeting the Retina to Slow or Stop Vision Loss or Restore Sight Development Pipeline of Proprietary Small Molecule Therapeutics Therapeutic Commercial Program Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Approach Rights Diseases of Retinal Ischemia CRAO Global Rights KIO-401 Calpain In

  5. Slide 5: KIO-401

    KIO-401 Small Molecule Calpain Inhibitor 5

  6. Slide 6: Calpains: Calcium-Activated Proteases in Ischemia Injury

    Calpains: Calcium-Activated Proteases in Ischemia Injury What are Calpains? How Ischemia Activates Calpains § Calpains are a family of calcium- Ischemia Energy Failure Calcium Overload Calpain Activation Proteolysis of Substrates activated cysteine proteases and Cell Death § Ubiquitously expressed i

  7. Slide 7: Central Retinal Artery Occlusion – An Acute Stroke of the Eye

    Central Retinal Artery Occlusion – An Acute Stroke of the Eye A Disease with No Available Treatments Over 80% of patients have permanent, severe vision loss (worse than 20/200) Central retinal artery Oxygen and nutrients Irreversible Time is critical becomes occluded are cut off vision loss Blood fl

  8. Slide 8: KIO-401: Phase 2a Study Design

    KIO-401: Phase 2a Study Design* Randomized, Dose Escalating, Multi-Center (Japan Only), Clinical Trial Cohort 1: KIO-401 (n=9) (100mg/day) Post Treatment ObservaFon Cohort 2: KIO-401 (n=10) Within 48 hrs of (200 mg/day) onset of symptoms Prospective Observational Registry (n=9) Day 1 Day 2 Day 8 Day

  9. Slide 9: KIO-401: Phase 2a Study Results

    KIO-401: Phase 2a Study Results* Mean Change from Baseline in ETDRS Letters 12P)4(#'(*R64*(#'7+( )*+,-.L01,*23L456)07 0" p = 0.070 V:22:;+L46<-=>:L?;@AL5-+:.*=:7 (! !""#$% C""#$% 8(,9(4+7%(#:;< #! /" '(%)*+,-#./0+,/1 '! ." "! C! } p = 0.0398 &" ! " ! "! #! A! B! C!! - % % +, $ $ 8-3 )* "# "# (% !" &

  10. Slide 10: KIO-401: Phase 3 Study Design

    KIO-401: Phase 3 Study Design* Randomized, Controlled, 14 Sites (Japan Only) Clinical Trial KIO-401 (n=33) Post Treatment Observation Within 48 hrs of (200 mg/day) onset of symptoms Placebo Control (n=30) Post Treatment Observation Day 1 Day 2 Day 8 Day 15 Day 29 Day 57 Visit 1 Visit 2 Visit 3 Visit

  11. Slide 11: KIO-401: Phase 3 Study Results

    KIO-401: Phase 3 Study Results* Mean Change from Baseline in ETDRS Letters (Observed Data Only) C'()*+,-.)'L0,123C-4 /0'12*#P*4R,24*#P(6* 86LL6V(,13W*;<6,=V>?,2*(6+';64 ." B! !"#$%&' ,//(01()*+2/. A" !"#$%&'()*+,-. &*7)*26(%*#89: -" A! #" #! } p = 0.0949 !" " " ! !""#$% &'()*+, ! " #! #" 5667 C'()*+

  12. Slide 12: KIO-401: Phase 3 Study Results

    KIO-401: Phase 3 Study Results* Categorical Visual Function Improvement 12 * Study was conducted by Senju

  13. Slide 13: KIO-401: Phase 3 Study Results

    KIO-401: Phase 3 Study Results* Safety – TEAE Summary (Treatment and Post-treatment Phases) Placebo KIO-401 (200 mg) (N=33) (N=33) n (%) events n (%) events Any TEAEs 10 (30.3) 17 13 (39.4) 21 Mild 7 (21.2) 13 9 (27.3) 17 Moderate 2 (6.1) 3 4 (12.1) 4 Severe 1 (3.0) 1 0 0 Serious TEAEs 3 (9.1) 3 1 (

  14. Slide 14: KIO-401: CRAO Planned Global Phase 3 Study Design

    KIO-401: CRAO Planned Global Phase 3 Study Design Randomized, Controlled, up to 50 Sites (US/EU/Asia) Registration, Clinical Trial KIO-401 (n~72) Post Treatment Within 48 hrs of (200 mg/day) Observation onset of symptoms Post Treatment Placebo Control (n~72) Observation Day 1 Day 2 Day 8 Day 15 Day

  15. Slide 15: NAION: Traditional Therapy Has No Current Options

    NAION: Traditional Therapy Has No Current Options Sudden, Irreversible Vision Loss with No Approved Therapy Severe, Irreversible Tx Initiated Within 2 No Current Treatment Limited Near-Term Vision Loss Weeks Today Options Sudden, painless vision loss in Most patients present days to No medical or su

  16. Slide 16: KIO-401 Is Poised to Offer a New Solution for NAION Pts

    KIO-401 Is Poised to Offer a New Solution for NAION Pts An Oral Neuroprotectant with a Phase 3 Signal in Acute Ischemic Optic Injury Established Treatment Proven Mechanism of Simple Route of Rapid Path to Action Signal Administration Value Creation Oral neuroprotection aimed at In CRAO paFents legal

  17. Slide 17: KIO-401: NAION Planned Phase 2b Study Design

    KIO-401: NAION Planned Phase 2b Study Design Randomized, Controlled, Registration-able, Clinical Trial KIO-401 (n~136) Within 14 days of (200 mg/day) onset of symptoms Placebo Control (n~136) Day 1 Day 14 Day 28 Day 56 Day 84 Day 112 Day 168 Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 §

  18. Slide 18: KIO-301

    KIO-301 18 | @KIORA

  19. Slide 19: KIO-301 (MOA): Turns RGCs "ON" in the Presence of Light

    KIO-301 (MOA): Turns RGCs “ON” in the Presence of Light § When photoreceptors die ⟶ downstream neurons (RGCs) are not capable of being activated § KIO-301 preferentially enters these RGCs and turns them “ON” in the presence of light* KIO-301 Extracellular P2X7‡ KV/HCN Channels trans • KIO-301 lodges

  20. Slide 20: In Patients with RP, Downstream Neurons Remain Viable

    In Patients with RP, Downstream Neurons Remain Viable RGC Bipolar Cell Rod Cone To the brain (connection intact) Bipolar cells and RGCs relay signal from rods and cones to Photoreceptors (rods and cones) sense light and pass the brain, where the image is “processed” the signal to special transmiong

  21. Slide 21: KIO-301 Reanimates the Retina & Changes Behaviour

    KIO-301 Reanimates the Retina & Changes Behaviour Extensive Validation in Preclinical Models Before KIO-301 After KIO-301 Light Dark 21 Neuron 2014: 81, 800-813.

  22. Slide 22: KIO-301: Phase 1b Study Design (ABACUS)

    KIO-301: Phase 1b Study Design (ABACUS) Open Label, Single Ascending Dose Trial – 2 Sites (Australia) Cohort 1: KIO-301 Cohort 1: KIO-301 (7.5 µg) Contralateral (25 µg) N=6 3/cohort Binocular Cohort 2: KIO-301 Cohort 2: KIO-301 (25 µg) Contralateral (50 µg) Day 7-8 Day 29-30 Visit 3 Visit 5 Day -120

  23. Slide 23: Changes in Vision & Patient QoL

    Changes in Vision & Patient QoL Kinetic Visual Field Visual Acuity Mean Change from BL ± 80% CL Mean ± SEM #%&! D"+!() #%#& D$C!() *H +,-./M D*!() * #%!! $F D"!() "%D& !""#$%C'( !"# !$# # $# "# B# C# "%&! D,-.,,L01203456-,02.170(5L,896, ! "! #! A! *p<0.05 ()* High Contrast Room Exit Test Quality of

  24. Slide 24: Functional MRI

    Func^onal MRI Significant Increase of CorZcal AcZvity DEE)*)+,-./M1+O3 45O,S.7.8V5: =M3O->.4/?,S@O.A1MB.C,>O-)SO: !CBB ! !"#$%&%' !BBB ! ! "CBB "BBB CBB B ! "# !A ;,< a--.V<O>.4SE"!: NLP – No Light PercepPon, BLP – Bare Light PercepPon, CF – CounPng Fingers 24 Nature Medicine v32, 1865–1870 (2026)

  25. Slide 25: KIO-301: Phase 2 Randomized, Controlled Clinical Trial (ABACUS-2)

    KIO-301: Phase 2 Randomized, Controlled Clinical Trial (ABACUS-2) Multiple Dose, Bilateral Injection, Double-Masked, 36-Patient, Randomized, Controlled Trial 50 µg KIO-301 100 µg KIO-301 Ultra Low Vision (ULV, n=8) ULV (n=8) No Light Perception (NLP, n=4) NLP (n=4) Vehicle Controls (n=6) Vehicle Con

  26. Slide 26: KIO-301: Global Partnership Network

    KIO-301: Global Partnership Network Significant Upside Opportunity via Milestones and RoyalZes 26

  27. Slide 27: Leadership and KOLs

    Leadership and KOLs 27 | @KIORA

  28. Slide 28: Leadership Team

    Leadership Team Brian M. Strem, PhD Melissa Tosca, CPA Stefan Sperl, PhD Keith Lane, MBA President & CEO Chief Financial Officer EVP – CMC, NonClin, IP EVP – Clin Dev & Regulatory LinkedIn LinkedIn LinkedIn LinkedIn 28

  29. Slide 29: Key Opinion Leaders

    Key Opinion Leaders KIO-401 Roger Goldberg, MD, PhD Allen Ho, MD, PhD Brian Mac Grory, MD, PhD Taiji Sakamoto, MD, PhD Charlie Wykoff, MD, PhD KIO-301 Christine Kay, MD, PhD Mark Pennesi, MD, PhD Russell Van Gelder, MD, PhD Vitreo Retinal ASSOCIATES 29

Kiora Pharmaceuticals — Investor Presentation (October 2026) on 6ix